February 23, 2018
KEY POINTS ERK inhibitors are the new class of drugs in development for resistant cancers Merck’s ERK inhibitor, MK-8353 in ...
Access articles & resources worth up to US $4, 000 per month.
Most up-to-date information, original and in-depth reviews, full-length exclusive market reports and forecasts, full-access to the smart knowledge base centres, useful resources and databases.
Access articles & resources worth up to $4000.
This New Cancer Drug Signifies ‘No Return of a Rare Blood Cancer’
15 Promising New Cancer Drugs in Late-Stage Clinical Development (2018)
Novel EGFR Lung Cancer Drug, Dacomitinib Gains FDA Priority Review
New Potential Immuno-Oncology Drug for Blood Cancer Received Orphan Drug Status
7 New Ideas to Start a Healthcare Business in India (2018)
Pharma Patents: Can India Reward Incremental Innovation?